A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Phase 1

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Placebo; Drug: SP-624

• Registration Number: NCT04510298
• Lead Sponsor: Sirtsei Pharmaceuticals, Inc.

Brief Summary

This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-27
• Study First Submitted QC: 2020-08-10
• Study First Posted: 2020-08-12
• Study Start: 2020-10-15
• Primary Completion: 2021-04-15
• Study Completion: 2021-04-15
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-18
• Last Update Posted: 2022-04-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Is willing and able to provide written informed consent to participate in the study.

• Has an identified reliable informant.

• Is, in the investigator's opinion, suitable for initiating a washout from the subject's current antipsychotic regimen, if applicable, and is willing to abstain from prohibited psychotropic medications in accordance with study requirements.

  • Subjects must meet screening eligibility criteria and be in an inpatient setting prior to discontinuing antipsychotic medications.
  • Subject must be able, in the investigator's opinion, to safely discontinue prohibited psychotropic medications prior to Baseline without increased suicidality.

• Has a primary diagnosis of schizophrenia based on the Diagnostic and Statistical Manual 5th edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Psychotic Disorders Studies.

• Is experiencing an acute exacerbation or relapse of symptoms.

• Is in generally good physical health, in the investigator's opinion, based on Screening medical history, physical examination, vital signs, and clinical laboratory values.

• Has a body mass index (BMI) between 18 and 40 kg/m2, inclusive.

• For women of reproductive potential: has a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline.

• For women of reproductive potential and men with female partners of reproductive potential: agrees to remain abstinent from sexual intercourse or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug.

Key

Exclusion Criteria

• Is a woman who is pregnant, breastfeeding, or less than 6 months postpartum at Screening.
• Has any primary DSM-5 disorder other than schizophrenia, as confirmed by the MINI.
• Fails to discontinue prohibited psychotropic medications.
• Has, in the investigator's opinion, a significant risk of violent or destructive behavior.
• Is currently hospitalized involuntarily or incarcerated.
• Has a history or presence of any clinically significant medical condition, disease, or surgical history that could, in the investigator's opinion, jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug.
• Is, in the investigator's opinion, not a suitable candidate for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo oral capsule, once daily
SP-624	SP-624	SP-624 oral capsule, 20 mg once daily

Primary Outcome Measures

Name	Time	Method
Incidence of Adverse Events (AEs)	Up to 8 weeks

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in Pulse Rate (beats per minute)	Up to 4 weeks	Pulse rate is measured by sphygmomanometer. Change from baseline measurement will be calculated
Number of Participants with Abnormal Clinical Laboratory Values	Up to 4 weeks	chemistry, hematology, and urinalysis tests will be performed
Change from Baseline in Body Weight (kilograms)	Up to 4 weeks	Body weight is measured by weight scale. Measurement is reported in kilograms. Change from Baseline measurement will be calculated.
Change from Baseline in Blood Pressure (mmHg)	Up to 4 weeks	Blood pressure is measured by sphygmomanometer. Change from baseline measurement will be calculated
Change from Baseline in Body Temperature (degrees celsius)	Up to 4 weeks	Body temperature is measured by oral thermometer. Change from baseline measurement will be calculated
Change from Baseline in ECG Heart Rate (beats per minute)	Up to 4 weeks	Heart rate is measured by 12-lead electrocardiogram (ECG). Change from Baseline measure will be calculated.
Change from Baseline in ECG RR Interval (seconds)	Up to 4 weeks	RR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Change from Baseline in ECG PR Interval (milliseconds)	Up to 4 weeks	PR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Change from Baseline in ECG QTcF Interval (milliseconds)	Up to 4 weeks	QTcF is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Number of Participants with Abnormal Physical Examination Findings	Up to 4 weeks
Number of Participants with treatment-emergent suicidal ideation or behavior	Up to 5 weeks	Treatment-emergent suicidal ideation and/or behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments
Number of Participants with treatment-emergent abnormal movements	Up to 4 weeks	Treatment-emergent abnormal movements will be assessed using a battery of movement assessments

Trial Locations

Locations (2)

Collaborative Neuroscience Research; 🇺🇸 Garden Grove, California, United States

Hassman Research Institute; 🇺🇸 Marlton, New Jersey, United States